Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update - PubMed (original) (raw)
Review
Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update
Franco Scaldaferri et al. World J Gastroenterol. 2016.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory disease, whose etiology is still unclear. Its pathogenesis involves an interaction between genetic factors, immune response and the "forgotten organ", Gut Microbiota. Several studies have been conducted to assess the role of antibiotics and probiotics as additional or alternative therapies for Ulcerative Colitis. Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negative strain isolated in 1917 by Alfred Nissle and it is the active component of microbial drug Mutaflor(®) (Ardeypharm GmbH, Herdecke, Germany and EcN, Cadigroup, In Italy) used in many gastrointestinal disorder including diarrhea, uncomplicated diverticular disease and UC. It is the only probiotic recommended in ECCO guidelines as effective alternative to mesalazine in maintenance of remission in UC patients. In this review we propose an update on the role of EcN 1917 in maintenance of remission in UC patients, including data about efficacy and safety. Further studies may be helpful for this subject to further the full use of potential of EcN.
Keywords: Escherichia coli Nissle; Inflammatory bowel disease; Metanalysis; Probiotic; Randomized trial; Ulcerative colitis.
Figures
Figure 1
Structure and mechanisms of action of Escherichia coli Nissle 1917. LPS: Lipopolysaccharide; IL-2: Interleukin-2; TNF: Tumor necrosis factor; IFN: Interferon.
Figure 2
Metanalysis on randomized controlled trials assessing role of Escherichia coli Nissle on maintenance of remission in ulcerative colitis.
Similar articles
- Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study.
Henker J, Müller S, Laass MW, Schreiner A, Schulze J. Henker J, et al. Z Gastroenterol. 2008 Sep;46(9):874-5. doi: 10.1055/s-2008-1027463. Epub 2008 Sep 22. Z Gastroenterol. 2008. PMID: 18810672 - Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial.
Petersen AM, Mirsepasi H, Halkjær SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Petersen AM, et al. J Crohns Colitis. 2014 Nov;8(11):1498-505. doi: 10.1016/j.crohns.2014.06.001. Epub 2014 Jun 25. J Crohns Colitis. 2014. PMID: 24972748 Clinical Trial. - Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Kruis W, et al. Gut. 2004 Nov;53(11):1617-23. doi: 10.1136/gut.2003.037747. Gut. 2004. PMID: 15479682 Free PMC article. Clinical Trial. - Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis.
Losurdo G, Iannone A, Contaldo A, Ierardi E, Di Leo A, Principi M. Losurdo G, et al. J Gastrointestin Liver Dis. 2015 Dec;24(4):499-505. doi: 10.15403/jgld.2014.1121.244.ecn. J Gastrointestin Liver Dis. 2015. PMID: 26697577 Review. - [The role of Escherichia coli strain Nissle 1917 in the gastro-intestinal diseases].
Różańska D, Regulska-Ilow B, Choroszy-Król I, Ilow R. Różańska D, et al. Postepy Hig Med Dosw (Online). 2014 Nov 6;68:1251-6. doi: 10.5604/17322693.1127882. Postepy Hig Med Dosw (Online). 2014. PMID: 25380207 Review. Polish.
Cited by
- Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products.
Kim DY, Lee SY, Lee JY, Whon TW, Lee JY, Jeon CO, Bae JW. Kim DY, et al. Gut Microbes. 2024 Jan-Dec;16(1):2412376. doi: 10.1080/19490976.2024.2412376. Epub 2024 Oct 8. Gut Microbes. 2024. PMID: 39377231 Free PMC article. Review. - Advancements in gene editing technologies for probiotic-enabled disease therapy.
Wang L, Hu J, Li K, Zhao Y, Zhu M. Wang L, et al. iScience. 2024 Aug 22;27(9):110791. doi: 10.1016/j.isci.2024.110791. eCollection 2024 Sep 20. iScience. 2024. PMID: 39286511 Free PMC article. Review. - Benefits and concerns of probiotics: an overview of the potential genotoxicity of the colibactin-producing Escherichia coli Nissle 1917 strain.
Falzone L, Lavoro A, Candido S, Salmeri M, Zanghì A, Libra M. Falzone L, et al. Gut Microbes. 2024 Jan-Dec;16(1):2397874. doi: 10.1080/19490976.2024.2397874. Epub 2024 Sep 4. Gut Microbes. 2024. PMID: 39229962 Free PMC article. Review. - Insights into Probiotic Prescription among Gastroenterologists and Other Healthcare Professionals: Evidence from an Italian Survey.
Marasco G, Bruni A, Nardone OM, Lopetuso LR. Marasco G, et al. J Clin Med. 2024 Aug 13;13(16):4749. doi: 10.3390/jcm13164749. J Clin Med. 2024. PMID: 39200891 Free PMC article. - Potential of using an engineered indole lactic acid producing Escherichia coli Nissle 1917 in a murine model of colitis.
Dimopoulou C, Guerra PR, Mortensen MS, Kristensen KA, Pedersen M, Bahl MI, Sommer MAO, Licht TR, Laursen MF. Dimopoulou C, et al. Sci Rep. 2024 Jul 30;14(1):17542. doi: 10.1038/s41598-024-68412-9. Sci Rep. 2024. PMID: 39080343 Free PMC article.
References
- Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390–407. - PubMed
- Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, Raupach B, Sonnenborn U, Eckert J, Schumann RR, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun. 2006;74:4075–4082. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical